Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868754 | 1.00 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL11470202 | 0.85 | KDM4E (0.50) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL11470204 | 0.85 | KDM4E (0.50) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL6785741 | 0.84 | KMT2A (0.54) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL3608805 | 0.78 | ALDH1A1 (0.50) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL8175156 | 0.77 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1LMNARAB9A | |
| SCHEMBL30317323 | 0.77 | NPC1 (0.62) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL11999774 | 0.77 | NPC1 (0.62) | ALDH1A1KMT2AMEN1LMNAPKM | |
| SCHEMBL692605 | 0.77 | MEN1 (0.87) | ALDH1A1KMT2AMEN1LMNARAB9A | |
| SCHEMBL692499 | 0.77 | MEN1 (0.87) | ALDH1A1KMT2AMEN1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184281-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184281-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | ALDH1A1 1573/4885KMT2A 2175/4885MEN1 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.